Trial · NCT07497282
Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis
NCT07497282, Phase 2, Not yet recruiting, Ain Shams University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis. Trials, record NCT07497282. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07497282
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis
- NCT number
- NCT07497282
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 70 participants, estimated
- Lead sponsor
- Ain Shams University
- Conditions
- Rheumatoid Arthritis
- Interventions
- venlafaxine extended-release (XR), Standard conventional Rheumatoid Arthritis Therapy
- First posted
- 2026-03-27
- Last updated
- 2026-03-27
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Disease Activity Score 28 (DAS28-CRP) | Baseline and 3 months | Disease severity will be assessed using DAS-28-CRP Disease activity will be assessed using the Disease Activity Score in 28 joints with C-reactive protein (DAS28-CRP), a validated composite index that includes tender joint count (28 joints), swollen joint count (28 joints), C-reactive protein (CRP), and patient global assessment of health. The DAS28-CRP score ranges approximately from 0 to 9.4, with higher scores indicating higher disease activity and worse outcomes. |
| Secondary | Change in C-reactive protein (CRP) | Baseline and 3 months | Serum C-reactive protein (CRP) levels will be measured as an indicator of systemic inflammation. CRP is expressed in mg/L, with higher values indicating increased inflammatory activity. |
| Secondary | Change in erythrocyte sedimentation rate (ESR) | Baseline and 3 months | Erythrocyte sedimentation rate (ESR) will be measured as a marker of inflammation. ESR is expressed in mm/hour, with higher values indicating increased inflammatory activity. |
| Secondary | Change in serum vascular endothelial growth factor (VEGF) | at baseline and after 3 months. | To investigate the change in serum vascular endothelial growth factor (VEGF) levels before and after venlafaxine treatment. A blood sample will be withdrawn from each patient at baseline and after 3 month and the separated sera will be stored at -80o C till analysis. These sera will be used to assess the level of VEGF using commercial ELISA kits. |
| Secondary | safety and tolerability of venlafaxine | at baseline and after 3 months. | To evaluate the safety and tolerability of venlafaxine through monitoring and documentation of potential adverse events during the study period |
| Secondary | Health assessment questionnaire HAQ-DI. | at baseline and after 3 months. | It consists of 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and activities, with 2-3 questions per domain. Each question is scored from 0 (no difficulty) to 3 (unable to do). The domain score is determined by the highest response within that domain. If an assistive device or help from another person is required, the minimum score for that domain is 2 (unless the score is already ≥ 2). The total HAQ-DI score is calculated by summing the 8 domain scores and dividing by 8. The final score ranges from 0 to 3, with higher scores indicating greater disability. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07497282
GET https://conductscience.org/api/trials/v1/NCT07497282/registered